Date of Award


Document Type

Open Access Thesis

Degree Name

Master of Medical Science (MMSc)

First Advisor

Geoffrey R. Connors, MD


Septic shock, a severe inflammatory state secondary to a bacterial infection with refractory hypotension and tissue hypoperfusion despite adequate fluid resuscitation, is a leading cause of mortality in intensive care units worldwide. The mortality rate of septic shock patients can exceed 40% in the U.S., highlighting the need for more effective therapies. Anakinra, an inflammatory cytokine inhibitor, has been identified as a potential therapy for reducing various inflammatory states such as sepsis. Our aim is to evaluate the efficacy of anakinra in reducing mortality in patients with septic shock. This double-blind, randomized control trial will compare the 28-day mortality of patients who receive a 72-hour intravenous infusion of anakinra to a group of patients treated by standard of care alone for septic shock in an intensive care setting. Our goal is to evaluate if the addition of anakinra to standard sepsis care will result in a significant mortality reduction in patients with septic shock.

Open Access

This Article is Open Access